AHFS April 2024 Update

This update contains 4 new monographs and 33 revised monographs.

New monographs: Eflornithine Hydrochloride; Sildenafil Citrate (Pulmonary Hypertension); Tadalafil (Pulmonary Hypertension); Taurolidine and Heparin Sodium.

Revised monographs: Abacavir Sulfate; Adagrasib; Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl; Avapritinib; Belimumab; Belzutifan; Cobimetinib Fumarate; Dexmedetomidine Hydrochloride; Dolutegravir Sodium and Lamivudine; Dolutegravir Sodium and Rilpivirine Hydrochloride; Dupilumab; Elexacaftor, Tezacaftor, and Ivacaftor; Fremanezumab-vfrm; Ibalizumab-uiyk; Ivacaftor; Rozanolixizumab-noli; Semaglutide; Sildenafil Citrate (Erectile Dysfunction); Sotorasib; Sparsentan; Tadalafil (Erectile Dysfunction, Benign Prostatic Hyperplasia); Tazemetostat Hydrobromide; Tenofovir Disoproxil Fumarate; Tepotinib Hydrochloride; Tesamorelin Acetate; Tezacaftor and Ivacaftor; Tralokinumab-ldrm; Ubrogepant; Vandetanib; Vismodegib; Vosoritide; Voxelotor ; Zavegepant Hydrochloride.